Erratum: Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects (Clinical Pharmacology and Therapeutics (2007) DOI: 10.1038/sj.clpt.6100075);Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 3, 2007, Pages 414-419

  Van Giersbergen, P L M ^a   Treiber, A ^a   Schneiter, R ^a   Dietrich, H ^b   Dingemanse, J ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b ClinPharmCologne   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DRUG METABOLITE; ORGANIC ANION TRANSPORTER 1; RIFAMPICIN; RO 47 8634; RO 48 5033; RO 64 1056; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CHO CELL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG METABOLISM; DRUG POTENTIATION; DRUG UPTAKE; ENZYME ACTIVATION; ENZYME INDUCTION; FEMALE; HUMAN; IN VITRO STUDY; LIVER METABOLISM; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ADULT; ALGORITHMS; ANTIBIOTICS, ANTITUBERCULAR; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; MIDDLE AGED; RIFAMPIN; SULFONAMIDES;

EID: 33847634378     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100166     Document Type: Erratum

References (32)

1. Channick, R.N. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358, 1119-1123 (2001).
2. Dingemanse, J. & Van Giersbergen, P.L.M. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet. 43, 1089-1115 (2004).
3. Weber, C., Gasser, R. & Hopfgartner, G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug. Metab. Disp. 27, 810-815 (1999).
4. Humbert, M., Nunes, H., Sitbon, O., Parent, F., Herve, P. & Simonneau, G. Risk factors for pulmonary arterial hypertension. Clin. Chest. Med. 22, 459-475 (2001).
5. Sitbon, O. et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am. J. Respir. Crit. Care. Med. 170, 1212-1217 (2004).
6. Davies, P.D. Risk factors for tuberculosis. Monaldi. Arch. Chest. Dis. 63, 37-46 (2005).
7. Alivu, M.H. & Salihu, H.M. Tuberculosis and HIV disease: two decades of a dual epidemic. Wien. Klin. Wochenschr. 31, 685-697 (2003).
8. Burman, W.J. Issues in the management of HIV-related tuberculosis. Clin. Chest. Med. 26, 283-294 (2005).
9. Niemi, M., Backman, J.T., Fromm, M.F., Neuvonen, P.J. & Kivistö , K.T. Pharmacokinetic interactions with rifampicin. Clinical relevance. Clin. Pharmacokinet. 42, 819-850 (2003).
10. Weber, C. et al. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J. Clin. Pharmacol. 39, 703-714 (1999).
11. Van Giersbergen, P.L.M., Gnerre, C., Treiber, A., Dingemanse, J. & Meyer, U.A. Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor. Eur. J. Pharmacol. 450, 115-121 (2002).
12. Kay, L. et al. Influence of rifampicin and isoniazid on the kinetics of phenytoin. Br. J. Clin. Pharmacol. 20, 323-326 (1985).
13. Lim, M.L. et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J. Acquir. Immune. Defic. Syndr. 36, 1034-1040 (2004).
14. Weber, C. et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin. Pharmacol. Ther. 60, 124-137 (1996).
15. Levy, G. Pharmacologic target-mediated drug disposition. Clin. Pharmacol. Ther. 56, 248-252 (1994).
16. Treiber, A., Schneiter, R., Delahaye, S. & Clozel, M. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporine A in the rat. J. Pharmacol. Exp. Ther. 308, 1121-1129 (2004).
17. Van Giersbergen, P.L.M., Halabi, A. & Dingemanse, J. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br. J. Clin. Pharmacol. 53, 589-595 (2002).
18. Kajosaari, L.I., Laitila, J., Neuvonen, P.J. & Backman, J.T. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of fibrates and rifampicin. Basic Clin. Pharmacol. Toxicol. 7, 249-256 (2005).
19. Iwasaki, K., Matsuda, H., Nagase, K., Shiraga, T., Tokuma, Y. & Uchida, K. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. Res. Commun. Chem. Pathol. Pharmacol. 82, 209-216 (1993).
20. Vavricka, S.R., Van Montfoort, J., Ha, H.R., Meier, P.J. & Fattinger, K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36, 164-172 (2002).
21. Shitara, Y. et al. Comparative inhibitory effects of different compounds on rat oatp1 (slc21a1)- and oatp2 (Slc21a5)-mediated transport. Pharm. Res. 19, 147-153 (2002).
22. Acocella, G. Clinical pharmacokinetics of rifampicin. Clin. Pharmacokinet. 3, 108-127 (1978).
23. Lau, Y.Y., Okochi, H., Huang, Y. & Benet, L.Z. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug. Metab. Dispos. 34, 1175-1181 (2006).
24. Jigorel, E., Le Vee, M., Boursier-Neyret, C., Parmentier, Y. & Fardel, O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug. Metab. Dispos. 34, 1756-1763.
25. Tirona, R.G., Leake, B.F., Wolkoff, A.W. & Kim, R.B. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 304, 223-228 (2003).
26. Busk Bidstrup, T., Stilling, N., Damkier, P., Scharling, B., Søndergård-Thomsen, M. & Brøsen, K. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur. J. Clin. Pharmacol. 60, 109-114 (2004).
27. Lam, J.L., Shugarts, S.B., Okochi, H. & Benet, L. Elucidating the effect of final day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J. Pharmacol. Exp. Ther. 319, 864-870 (2006).
28. Dell, D., Lausecker, B., Hopfgartner, G., Van Giersbergen, P.L.M. & Dingemanse, J. Evolving bioanalytical methods for the cardiovascular drug bosentan. Chromatographia 55(Suppl): S115-S119 (2002).
29. Leemann, T., Transon, C. & Dayer, P. Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life. Sci. 52, 29-34 (1993).
30. Walsky, R.L. & Obach, R.S. Validated assays for human cytochrome P450 activities. Drug. Metab. Dispos. 32, 647-660 (2004).
31. Shimizu, M. et al. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug. Metab. Dispos. 33, 1477-1481 (2005).
32. Dingemanse, J., Schaarschmidt, D. & Van Giersbergen, P.L.M. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin. Pharmacokinet. 42, 293-301 (2003).